TY - JOUR
T1 - Toki-shakuyaku-san, a Japanese kampo medicine, reduces colon inflammation in a mouse model of acute colitis
AU - Sreedhar, Remya
AU - Arumugam, Somasundaram
AU - Thandavarayan, Rajarajan A.
AU - Giridharan, Vijayasree V.
AU - Karuppagounder, Vengadeshprabhu
AU - Pitchaimani, Vigneshwaran
AU - Afrin, Rejina
AU - Harima, Meilei
AU - Nakamura, Takashi
AU - Ueno, Kazuyuki
AU - Nakamura, Masahiko
AU - Suzuki, Kenji
AU - Watanabe, Kenichi
N1 - Funding Information:
We acknowledge both the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Promotion and Mutual Aid Corporation for Private Schools, Japan for their grant support ( 23602012 and 26460239 respectively).
Publisher Copyright:
© 2015 Elsevier B.V. All rights reserved.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Toki-shakuyaku-san (TOKI) is a Japanese kampo medicine, which consists of a mixture of herbal medicines and considered to be a promising remedial agent due to its immunomodulatory and anti-inflammatory effects. We examined the beneficial effects of TOKI in inflammatory bowel disease associated with the inflammation of the intestinal barrier. A study was designed, using C57BL/6 female mice and were administered with 3% DSS in drinking water for 8 days with or without 1 g/kg/day TOKI orally for the last 3 days and a normal group supplied with plain drinking water for 8 days. TOKI treatment attenuated the clinical symptoms of acute murine colitis and also alleviated the inflammatory mechanism by reducing the inflammatory mediators, such as IL-1β, IL-2, TGF-β, RAGE and TLR2. It has also decreased the levels of CHOP, caspase12, cleaved caspase3 and cleaved caspase7 and thereby down-regulated the endoplasmic reticulum stress and apoptotic signaling induced by DSS. Moreover, the expression levels of cyclin D1 and c-kit have also confirmed the beneficial role of TOKI in colitis. All these data suggested that TOKI can be a promising agent for the treatment of colitis since it alleviates the disease progression and severity.
AB - Toki-shakuyaku-san (TOKI) is a Japanese kampo medicine, which consists of a mixture of herbal medicines and considered to be a promising remedial agent due to its immunomodulatory and anti-inflammatory effects. We examined the beneficial effects of TOKI in inflammatory bowel disease associated with the inflammation of the intestinal barrier. A study was designed, using C57BL/6 female mice and were administered with 3% DSS in drinking water for 8 days with or without 1 g/kg/day TOKI orally for the last 3 days and a normal group supplied with plain drinking water for 8 days. TOKI treatment attenuated the clinical symptoms of acute murine colitis and also alleviated the inflammatory mechanism by reducing the inflammatory mediators, such as IL-1β, IL-2, TGF-β, RAGE and TLR2. It has also decreased the levels of CHOP, caspase12, cleaved caspase3 and cleaved caspase7 and thereby down-regulated the endoplasmic reticulum stress and apoptotic signaling induced by DSS. Moreover, the expression levels of cyclin D1 and c-kit have also confirmed the beneficial role of TOKI in colitis. All these data suggested that TOKI can be a promising agent for the treatment of colitis since it alleviates the disease progression and severity.
KW - Apoptosis
KW - Endoplasmic reticulum stress
KW - Inflammation
KW - Inflammatory bowel diseases
KW - Kampo medicine
KW - Toki-shakuyaku-san
UR - http://www.scopus.com/inward/record.url?scp=84948579114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948579114&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2015.08.029
DO - 10.1016/j.intimp.2015.08.029
M3 - Article
C2 - 26344429
AN - SCOPUS:84948579114
SN - 1567-5769
VL - 29
SP - 869
EP - 875
JO - International Immunopharmacology
JF - International Immunopharmacology
IS - 2
ER -